Objectives: Safety of gadolinium based contrast agents (GBCA) has been of increased interest since discovery of its association with nephrogenic systemic fibrosis (NSF). Although NSF has been virtually eliminated by preventive measures, immediate, allergic type hypersensitivity reactions remain a real, albeit rare GBCA safety issue. The purpose of this study was to systematically explore rates of adverse events for the GBCA used at our hospitals over the past 10 years and to assess how our local experience compares to reports made to the US FDA.
Results: Data on adverse events were available dating back to 2004 in one hospital and dating back to 2000 for the other hospital. Hospital quality assurance records detailed 140 events related to GBCA including 46 infiltrations (3 per 10,000 injections) and 94 GBCA acute adverse reactions (5.9 per 10,000 injections). Rate of adverse events for each type of GBCA is listed in Table 1 . Severe reactions occurred in 1/40,000 injections. Gadoteridol had the highest rate of adverse events, 3.3/1000 injections, but no arrests/deaths. Gadobenate dimeglumine had the highest rate of arrests involving activation of the code team, ~1 in 10,000 injections, which was significantly higher than the zero rate for gadodiamide and gadopentetate dimeglumine (p < 0.0001). Overall, ionic linear GBCA had a significantly higher rate of AE compared to nonionic linear GBCA (p < 0.0001). * Excluding infiltrations and each patient is counted once regardless of the number of symptoms' ** also known as gadobenate dimeglumine *** significantly higher than gadodiamide and gadopentetate dimeglumine with p < 0.05; **** significantly higher than gadodiamide and gadopentetate dimeglumine with p < 0.001; ***** Excluding 1 gadoxetate adverse event; ♣ also known as gadopentetate dimeglumine or Gd:DTPA Abdomen examinations had more than double the overall rate of reactions (13 vs 5.9 reactions per 10,000 exams) and was statistically significantly higher than the rate of GBCA AE for brain and spine MRI (p < 0.001). Compared to age/exam matched control patients, there were significantly more female patients with AE (F: M = 3.3) compared to 1.1 for control patients (p < 0.001). Adverse event patients also had a higher incidence of prior reactions to GBCA (p = 0.007) and more prior allergic events with 38/94 having a history of allergy compared to 16/94 for the controls (p < 0.001). All 3 arrests (patient becoming unresponsive and the code team called) occurred immediately following gadobenate dimeglumine injection. FDA AERS Database: From 2004 to 2009 there were a total of 40 deaths in the US reported to the FDA attributed to GBCA (excluding NSF). The death rate from adverse reactions to GBCA reported to the FDA was less than 1 in a million (40 deaths/51 million GBCA administrations). The patient age at the time of these GBCA deaths ranged from 9 months to 89 years (mean = 60 years) and interestingly the male:female ratio was 27:10 for the 37 deaths where gender was reported. After correcting for market share, there was an 18 times higher rate of death reported for gadobenate dimeglumine compared to gadodiamide (p < 0.0001). There was a 7-fold higher rate of death from adverse events for ionic linear agents compared to non-ionic linear agents (p < 0.0001) which mirrors the well-known experience with iodinated contrast.
Discussion: Data from our hospitals showed a rate of serious reactions of about 1/40,000 injections, similar to the rates reported by Murphy et al and Dillman et al. Dillman also noted a trend toward more reactions in female patients as well as greater risk in patients with an allergic reaction history. The overall rate of GBCA death reported to the FDA Medwatch database was less than 1 in a million (40 deaths in 51 million administrations), similar to the risk of death from traveling 86 miles by car. These data from our hospitals and from the FDA suggest the possibility of a lower adverse event rate for nonionic GBCA compared to ionic linear or macrocyclic GBCA. This may be partly due to the inherently lower osmolarity of nonionic agents which reduces osmo-toxicity, one of the causes of mast cell degranulation. Since the total number of hypersensitivity reaction deaths (~ 7 per year in US for all GBCA) far exceeds the number of deaths caused by NSF (near zero now that NSF has been nearly eliminated), allergic reaction risk should be considered in maximizing contrast agent safety. Although GBCA is extremely safe, death from hypersensitivity reactions and debilitating fibrosis are possible. These can be minimized by the skill and vigilance of the radiologist and MRI team.
